Immediate Impact
51 standout
Citing Papers
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
2024 Standout
Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial
2024 Standout
Works of San‐Chi Chen being referenced
Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment
2022
Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma
2020
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| San‐Chi Chen | 250 | 170 | 166 | 51 | 746 | |
| Akira Oshima | 194 | 93 | 125 | 42 | 932 | |
| Gregory Kouraklis | 180 | 164 | 137 | 43 | 785 | |
| Ángel Segura | 454 | 74 | 123 | 44 | 864 | |
| G. Berger | 191 | 91 | 137 | 39 | 708 | |
| Bang-li Hu | 238 | 82 | 161 | 63 | 828 | |
| Yoshimasa Miyauchi | 216 | 272 | 204 | 45 | 904 | |
| Tetsuro Kajiwara | 171 | 73 | 260 | 63 | 828 | |
| Peter Studer | 195 | 136 | 112 | 44 | 938 | |
| Sung‐Nan Pei | 123 | 271 | 82 | 46 | 837 | |
| Kewei Li | 171 | 154 | 346 | 43 | 959 |
All Works
Login with ORCID to disown or claim papers
Loading papers...